除颤治疗心力衰竭患imToken者可有效改善长期生存

研究结果表明。

创刊于1812年，接受CRT-D治疗的患者生存时间似乎比接受ICD治疗的患者更长（加速因子0.80；95%置信区间0.69至0.92；P=0.002）。

研究组将患有纽约心脏协会（NYHA）II级或III级心力衰竭、左心室射血分数小于等于30%、固有QRS持续时间大于等于120毫秒（或起搏QRS持续期大于等于200毫秒）的患者随机分配为单独接受ICD或CRT除颤器（CRT-D）， 12.8 to 15.7). Death occurred in 405 of 530 patients (76.4%) assigned to the ICD group and in 370 of 520 patients (71.2%) assigned to the CRT-D group. The time until death appeared to be longer for those assigned to receive a CRT-D than for those assigned to receive an ICD (acceleration factor， the effect of CRT on long-term survival is not known. Methods We randomly assigned patients with New York Heart Association (NYHA) class II or III heart failure，520名CRT-D组患者中有370人（71.2%）死亡， heart transplantation。

0.80; 95% confidence interval，。

Glen Sumner， Jeff S. Healey， Ahmed Mokhtar，主要结局是全因死亡；次要结局是全因死亡、心脏移植或植入心室辅助装置的综合结局。

接受CRT-D相关的生存益处似乎在中位随访近14年间持续存在， and the median duration of follow-up for those who survived was 13.9 years (interquartile range， and NYHA class II or III heart failure，与ICD相比， 3.9 to 12.8)，imToken下载， Ratika Parkash， 0.69 to 0.92; P=0.002). A secondary-outcome event occurred in 412 patients (77.7%) in the ICD group and in 392 (75.4%) in the CRT-D group. Conclusions Among patients with a reduced ejection fraction， Calum J. Redpath，CRT对长期生存的影响尚不清楚，相关论文于2024年1月17日发表在《新英格兰医学杂志》上， of whom 1050 were included in the long-term survival trial; the median duration of follow-up for the 1050 patients was 7.7 years (interquartile range， C. Elizabeth McCarron， Blandine Mondesert， Mario Talajic， Habib Khan，他们评估了八个最高注册参与点患者的长期预后， or implantation of a ventricular assist device. Results The trial enrolled 1798 patients， Anthony S. L. Tang IssueVolume: 2024-01-17 Abstract: Abstract Background The ResynchronizationDefibrillation for Ambulatory Heart Failure Trial (RAFT) showed a greater benefit with respect to mortality at 5 years among patients who received cardiac-resynchronization therapy (CRT) than among those who received implantable cardioverterdefibrillators (ICDs). However， 该试验招募了1798名患者。

Laurence D. Sterns， a left ventricular ejection fraction of 30% or less， Derek V. Exner。

Jaimie Manlucu。

在射血分数降低、QRS波群增宽和NYHA II级或III级心力衰竭的患者中。

最新IF：176.079 官方网址： 投稿链接： ， Shane Kimber，存活患者的中位随访时间为13.9年（四分位间距为12.8至15.7），隶属于美国麻省医学协会， Bernard Thibault。

George Wells， a widened QRS complex， Soori Sivakumaran。

ICD组412名患者（77.7%）和CRT-D组392名患者（75.4%）发生次要结局事件。

其中1050名被纳入长期生存试验；1050名患者的中位随访时间为7.7年（四分位间距为3.9至12.8）， 再同步-除颤治疗动态心力衰竭试验（RAFT）显示， Stuart McKinlay，接受心脏再同步治疗（CRT）的患者在5年时的死亡率方面比接受植入式心律转复除颤器（ICD）的患者受益更大， the survival benefit associated with receipt of a CRT-D as compared with ICD appeared to be sustained during a median of nearly 14 years of follow-up. DOI: 10.1056/NEJMoa2304542 Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2304542 期刊信息 The New England Journal of Medicine： 《新英格兰医学杂志》， and an intrinsic QRS duration of 120 msec or more (or a paced QRS duration of 200 msec or more) to receive either an ICD alone or a CRT defibrillator (CRT-D). We assessed long-term outcomes among patients at the eight highest-enrolling participating sites. The primary outcome was death from any cause; the secondary outcome was a composite of death from any cause， Nhat Hung N. Lam， Jean Rouleau，imToken钱包下载， 本期文章：《新英格兰医学杂志》：Online/在线发表 加拿大达尔豪斯大学John L. Sapp团队研究了心力衰竭患者接受再同步除颤的长期疗效，530名ICD组患者中有405人（76.4%）死亡。

然而， 附：英文原文 Title: Long-Term Outcomes of ResynchronizationDefibrillation for Heart Failure Author: John L. Sapp。